Spots Global Cancer Trial Database for refractory anemia with excess blasts in transformation
Every month we try and update this database with for refractory anemia with excess blasts in transformation cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies | NCT01175785 | Accelerated Pha... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Acute... Childhood Acute... Childhood Chron... Childhood Myelo... Chronic Phase C... de Novo Myelody... Previously Trea... Refractory Anem... Refractory Anem... Refractory Anem... Relapsing Chron... Secondary Myelo... | umbilical cord ... fludarabine pho... cyclophosphamid... ex vivo-expande... total-body irra... cyclosporine mycophenolate m... laboratory biom... | 6 Months - 45 Years | Nohla Therapeutics, Inc. | |
| Bryostatin 1 in Treating Patients With Myelodysplastic Syndrome | NCT00003171 | Leukemia Myelodysplastic... | bryostatin 1 | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation | NCT00052520 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... B-cell Adult Ac... B-cell Childhoo... Childhood Chron... Childhood Myelo... Chronic Myelomo... Essential Throm... Polycythemia Ve... Previously Trea... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Refractory Anem... Refractory Anem... Relapsing Chron... Secondary Acute... T-cell Adult Ac... T-cell Childhoo... | therapeutic all... aldesleukin peripheral bloo... allogeneic bone... laboratory biom... gene expression... immunologic tec... flow cytometry polymerase chai... cytogenetic ana... staining method | - | Fred Hutchinson Cancer Center | |
| Amifostine in Treating Patients With Advanced Myelodysplastic Syndrome | NCT00003123 | Myelodysplastic... | amifostine trih... | 17 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia | NCT00003602 | Leukemia Myelodysplastic... | cytarabine etoposide idarubicin mitoxantrone hy... | 55 Years - | National Cancer Institute (NCI) | |
| Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers | NCT00015951 | Leukemia Myelodysplastic... | bevacizumab cytarabine mitoxantrone hy... | 18 Years - 120 Years | University of Maryland, Baltimore | |
| Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia | NCT00357565 | Leukemia Myelodysplastic... Childhood Acute... Recurrent Child... Secondary Acute... Childhood Acute... Previously Trea... Secondary Myelo... Refractory Anem... Refractory Anem... Refractory Anem... De Novo Myelody... Childhood Myelo... | filgrastim busulfan cyclosporine fludarabine pho... melphalan mycophenolate m... umbilical cord ... | - 3 Years | Masonic Cancer Center, University of Minnesota | |
| Gemtuzumab in Treating Patients With Myelodysplastic Syndrome | NCT00022321 | Myelodysplastic... | gemtuzumab ozog... | 18 Years - | National Cancer Institute (NCI) | |
| Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy | NCT00891137 | Leukemia Lymphoma Multiple Myelom... Plasma Cell Neo... Myelodysplastic... | human myeloid p... | 12 Years - 65 Years | Cellerant Therapeutics | |
| VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies | NCT00070538 | Leukemia Myelodysplastic... | cytarabine laromustine | 18 Years - | National Cancer Institute (NCI) | |
| Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes | NCT00234000 | Leukemia Myelodysplastic... | arsenic trioxid... azacitidine | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Amifostine Plus Topotecan in Treating Patients With Myelodysplastic Syndrome | NCT00003415 | Leukemia Myelodysplastic... | amifostine trih... topotecan hydro... | 18 Years - | National Cancer Institute (NCI) | |
| Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome | NCT02553941 | Chronic Myelomo... de Novo Myelody... Previously Trea... Refractory Anem... Secondary Myelo... | Azacitidine Ibrutinib | 18 Years - | University of California, Davis | |
| Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic Syndrome | NCT00002800 | Leukemia Myelodysplastic... Neutropenia | filgrastim lintuzumab cytarabine etoposide idarubicin | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer | NCT00003661 | Graft Versus Ho... Leukemia Lymphoma Myelodysplastic... Neuroblastoma | anti-thymocyte ... busulfan cyclosporine melphalan methylprednisol... umbilical cord ... radiation thera... | - 54 Years | Roswell Park Cancer Institute | |
| BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia | NCT00006213 | Adult Acute Pro... Blastic Phase C... Childhood Myelo... Previously Trea... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Refractory Anem... Refractory Anem... Relapsing Chron... | BMS-214662 pharmacological... laboratory biom... | 15 Years - | National Cancer Institute (NCI) | |
| Chemotherapy in Treating Patients Who Have Hematologic Cancer | NCT00004047 | Leukemia Myelodysplastic... | exatecan mesyla... | - | Daiichi Sankyo | |
| Paricalcitol in Treating Patients With Myelodysplastic Syndrome | NCT00064376 | Leukemia Myelodysplastic... | paricalcitol | 25 Years - 100 Years | Cedars-Sinai Medical Center | |
| Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation | NCT00005641 | Chronic Myelopr... Graft Versus Ho... Leukemia Multiple Myelom... Myelodysplastic... | anti-thymocyte ... busulfan cyclophosphamid... cyclosporine leucovorin calc... methotrexate methylprednisol... allogeneic bone... in vitro-treate... radiation thera... | 15 Years - 60 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia | NCT00087204 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Blastic Phase C... Chronic Myelomo... de Novo Myelody... Previously Trea... Recurrent Adult... Recurrent Adult... Refractory Anem... Refractory Anem... Relapsing Chron... Secondary Acute... Secondary Myelo... | becatecarin laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes | NCT00997243 | Leukemia Myelodysplastic... | lintuzumab 5-azacytidine | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies | NCT00070538 | Leukemia Myelodysplastic... | cytarabine laromustine | 18 Years - | National Cancer Institute (NCI) | |
| Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome | NCT00119366 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Myelo... Chronic Myelomo... Previously Trea... Recurrent Adult... Recurrent Child... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... Secondary Acute... Secondary Myelo... | iodine I 131 mo... fludarabine pho... total-body irra... allogeneic hema... peripheral bloo... cyclosporine mycophenolate m... laboratory biom... | 16 Years - 50 Years | Fred Hutchinson Cancer Center | |
| S9920 Busulfan Compared With Cyclophosphamide in Patients Undergoing Total-Body Irradiation Plus Peripheral Stem Cell Transplantation for Advanced Myelodysplastic Syndrome or Related Acute Myeloid Leukemia | NCT00005866 | Leukemia Myelodysplastic... | busulfan cyclophosphamid... cyclosporine methotrexate allogeneic bone... radiation thera... | 16 Years - 55 Years | SWOG Cancer Research Network | |
| Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer | NCT00296023 | Chronic Myelopr... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | anti-thymocyte ... filgrastim therapeutic all... busulfan fludarabine pho... methotrexate tacrolimus nonmyeloablativ... peripheral bloo... | 18 Years - 75 Years | University of California, San Francisco | |
| Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia | NCT00002926 | Leukemia Myelodysplastic... | cytarabine etoposide idarubicin allogeneic bone... peripheral bloo... | 16 Years - 60 Years | National Cancer Institute (NCI) | |
| Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myeloid Leukemia | NCT00003436 | Leukemia Myelodysplastic... | amsacrine asparaginase cytarabine daunorubicin hy... etoposide methotrexate mitoxantrone hy... therapeutic hyd... allogeneic bone... | - 15 Years | National Cancer Institute (NCI) | |
| Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer | NCT00290641 | Chronic Myelopr... Leukemia Lymphoma Myelodysplastic... | filgrastim graft-versus-tu... cyclophosphamid... cyclosporine fludarabine pho... mycophenolate m... umbilical cord ... radiation thera... | - 45 Years | Masonic Cancer Center, University of Minnesota | |
| Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer | NCT00003661 | Graft Versus Ho... Leukemia Lymphoma Myelodysplastic... Neuroblastoma | anti-thymocyte ... busulfan cyclosporine melphalan methylprednisol... umbilical cord ... radiation thera... | - 54 Years | Roswell Park Cancer Institute | |
| Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome | NCT00002547 | Leukemia Myelodysplastic... | busulfan cyclophosphamid... cyclosporine cytarabine methotrexate allogeneic bone... syngeneic bone ... | - 60 Years | Barbara Ann Karmanos Cancer Institute | |
| Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome | NCT00002798 | Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Myelo... Chronic Myelomo... de Novo Myelody... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Anem... Secondary Myelo... Untreated Child... | asparaginase daunorubicin hy... fludarabine pho... therapeutic hyd... allogeneic bone... 3-dimensional c... filgrastim cytarabine idarubicin dexamethasone thioguanine etoposide methotrexate cyclophosphamid... aldesleukin busulfan | - 21 Years | National Cancer Institute (NCI) | |
| BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia | NCT00006213 | Adult Acute Pro... Blastic Phase C... Childhood Myelo... Previously Trea... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Refractory Anem... Refractory Anem... Relapsing Chron... | BMS-214662 pharmacological... laboratory biom... | 15 Years - | National Cancer Institute (NCI) | |
| Tipifarnib in Treating Patients With Advanced Hematologic Cancer | NCT00005967 | Chronic Myelopr... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| Monoclonal Antibody Therapy in Treating Patients With Primary Myelodysplastic Syndrome | NCT00003984 | Myelodysplastic... | lintuzumab | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy | NCT00005942 | Chronic Myelomo... Previously Trea... Recurrent Adult... Refractory Anem... Refractory Anem... | liposomal dauno... semaxanib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome | NCT00003827 | Leukemia Myelodysplastic... | amifostine trih... cytarabine topotecan hydro... | 16 Years - | National Cancer Institute (NCI) | |
| Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia | NCT00087204 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Blastic Phase C... Chronic Myelomo... de Novo Myelody... Previously Trea... Recurrent Adult... Recurrent Adult... Refractory Anem... Refractory Anem... Relapsing Chron... Secondary Acute... Secondary Myelo... | becatecarin laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Laboratory-Treated Lymphocyte Infusion After Haploidentical Donor Stem Cell Transplant | NCT00376480 | Leukemia Myelodysplastic... | anti-thymocyte ... peripheral bloo... fludarabine pho... methylprednisol... thiotepa allogeneic hema... in vitro-treate... total-body irra... | - 50 Years | Dana-Farber Cancer Institute | |
| Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy | NCT00006220 | Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | arsenic trioxid... tretinoin | 15 Years - | Washington University School of Medicine | |
| Donor Stem Cell Transplant in Treating Young Patients With Myelodysplastic Syndrome, Leukemia, Bone Marrow Failure Syndrome, or Severe Immunodeficiency Disease | NCT00295971 | Congenital Ameg... Leukemia Myelodysplastic... Severe Congenit... | anti-thymocyte ... therapeutic all... fludarabine pho... thiotepa allogeneic bone... allogeneic hema... in vitro-treate... total-body irra... | 1 Year - 17 Years | University of California, San Francisco | |
| Busulfan, Etoposide, and Total-Body Irradiation in Treating Patients Undergoing Donor Stem Cell or Bone Marrow Transplant for Advanced Hematologic Cancer | NCT00534430 | Leukemia Myelodysplastic... | busulfan cyclosporine etoposide mycophenolate m... allogeneic bone... allogeneic hema... peripheral bloo... total-body irra... | 16 Years - 50 Years | City of Hope Medical Center | |
| Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia | NCT01146210 | Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Myelo... Chronic Myelomo... de Novo Myelody... Fanconi Anemia Refractory Anem... Refractory Anem... Refractory Anem... Refractory Anem... Secondary Myelo... Untreated Child... | laboratory biom... | - 21 Years | Children's Oncology Group | |
| Laboratory-Treated Lymphocyte Infusion After Haploidentical Donor Stem Cell Transplant | NCT00376480 | Leukemia Myelodysplastic... | anti-thymocyte ... peripheral bloo... fludarabine pho... methylprednisol... thiotepa allogeneic hema... in vitro-treate... total-body irra... | - 50 Years | Dana-Farber Cancer Institute | |
| Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell Transplant | NCT00107354 | Leukemia Myelodysplastic... | aldesleukin therapeutic all... therapeutic aut... cytarabine etoposide mitoxantrone hy... allogeneic bone... peripheral bloo... | 14 Years - | Fred Hutchinson Cancer Center | |
| Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant and Immunosuppression Therapy in Treating Older Patients With Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes | NCT00008177 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Chronic Myelomo... de Novo Myelody... Previously Trea... Recurrent Adult... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... Secondary Myelo... Untreated Adult... | iodine I 131 mo... total-body irra... allogeneic hema... peripheral bloo... fludarabine pho... cyclosporine mycophenolate m... laboratory biom... | 50 Years - | Fred Hutchinson Cancer Center | |
| Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia | NCT00096122 | Adult Acute Bas... Adult Acute Eos... Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Childhood Myelo... Chronic Myelomo... de Novo Myelody... Refractory Anem... Refractory Anem... Secondary Acute... Secondary Myelo... Untreated Adult... | cytarabine idarubicin tipifarnib | 15 Years - 70 Years | National Cancer Institute (NCI) | |
| Amifostine & High-Dose Combination Chemotherapy in Treating Patients With Acute ML or CML | NCT00003407 | Drug/Agent Toxi... Leukemia Myelodysplastic... Neutropenia | amifostine trih... cytarabine mitoxantrone hy... | 18 Years - 120 Years | Rush University Medical Center | |
| Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia | NCT00096122 | Adult Acute Bas... Adult Acute Eos... Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Childhood Myelo... Chronic Myelomo... de Novo Myelody... Refractory Anem... Refractory Anem... Secondary Acute... Secondary Myelo... Untreated Adult... | cytarabine idarubicin tipifarnib | 15 Years - 70 Years | National Cancer Institute (NCI) | |
| Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myeloid Leukemia | NCT00003436 | Leukemia Myelodysplastic... | amsacrine asparaginase cytarabine daunorubicin hy... etoposide methotrexate mitoxantrone hy... therapeutic hyd... allogeneic bone... | - 15 Years | National Cancer Institute (NCI) | |
| Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia | NCT00046930 | Leukemia Myelodysplastic... | filgrastim sargramostim cytarabine daunorubicin hy... zosuquidar trih... Placebo | 60 Years - | Eastern Cooperative Oncology Group | |
| SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes | NCT00098826 | Acute Undiffere... Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Pro... Adult Erythrole... Adult Pure Eryt... Blastic Phase C... de Novo Myelody... Previously Trea... Recurrent Adult... Recurrent Adult... Refractory Anem... Refractory Anem... Relapsing Chron... Secondary Acute... Secondary Myelo... Untreated Adult... | ispinesib laboratory biom... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Topotecan in Treating Patients With Myelodysplastic Syndrome | NCT00003675 | Leukemia Myelodysplastic... | topotecan hydro... | 15 Years - 120 Years | Alliance for Clinical Trials in Oncology | |
| Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia | NCT00046930 | Leukemia Myelodysplastic... | filgrastim sargramostim cytarabine daunorubicin hy... zosuquidar trih... Placebo | 60 Years - | Eastern Cooperative Oncology Group | |
| Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia | NCT00002926 | Leukemia Myelodysplastic... | cytarabine etoposide idarubicin allogeneic bone... peripheral bloo... | 16 Years - 60 Years | National Cancer Institute (NCI) | |
| Fludarabine, Carboplatin, and Topotecan in Treating Patients With Relapsed/Refractory Acute Leukemia or Advanced Myelodysplastic Syndrome | NCT00005593 | Leukemia Myelodysplastic... | carboplatin fludarabine pho... topotecan hydro... | 12 Years - | Case Comprehensive Cancer Center | |
| Decitabine in Treating Patients With Myelodysplastic Syndrome | NCT00003361 | Leukemia Myelodysplastic... | decitabine | 15 Years - | National Cancer Institute (NCI) | |
| Gemtuzumab Ozogamicin, Fludarabine, and Total-body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome | NCT00008151 | Leukemia Myelodysplastic... | cyclosporine fludarabine pho... gemtuzumab ozog... methotrexate mycophenolate m... allogeneic bone... peripheral bloo... radiation thera... | - | Fred Hutchinson Cancer Center | |
| Monoclonal Antibody Therapy in Treating Patients With Primary Myelodysplastic Syndrome | NCT00003984 | Myelodysplastic... | lintuzumab | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Monoclonal Antibody Therapy in Treating Patients With Myelodysplastic Syndrome or Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelogenous Leukemia | NCT00002890 | Leukemia Myelodysplastic... | lintuzumab | 16 Years - | Memorial Sloan Kettering Cancer Center | |
| Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome | NCT02553941 | Chronic Myelomo... de Novo Myelody... Previously Trea... Refractory Anem... Secondary Myelo... | Azacitidine Ibrutinib | 18 Years - | University of California, Davis | |
| Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy | NCT00891137 | Leukemia Lymphoma Multiple Myelom... Plasma Cell Neo... Myelodysplastic... | human myeloid p... | 12 Years - 65 Years | Cellerant Therapeutics | |
| Dolastatin 10 in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia | NCT00003693 | Leukemia Myelodysplastic... | Dolastatin 10 | - | M.D. Anderson Cancer Center | |
| Decitabine in Treating Patients With Myelodysplastic Syndrome | NCT00003361 | Leukemia Myelodysplastic... | decitabine | 15 Years - | National Cancer Institute (NCI) | |
| PS-341 in Treating Patients With Hematologic Cancer | NCT00006098 | Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | bortezomib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes | NCT00098423 | Accelerated Pha... Adult Acute Bas... Adult Acute Eos... Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Blastic Phase C... Chronic Myelomo... de Novo Myelody... Previously Trea... Recurrent Adult... Recurrent Adult... Refractory Anem... Relapsing Chron... Secondary Acute... Secondary Myelo... | tanespimycin cytarabine | 18 Years - | National Cancer Institute (NCI) | |
| Amifostine Plus Topotecan in Treating Patients With Myelodysplastic Syndrome | NCT00003415 | Leukemia Myelodysplastic... | amifostine trih... topotecan hydro... | 18 Years - | National Cancer Institute (NCI) | |
| XK469R in Treating Patients With Refractory Hematologic Cancer | NCT00095797 | Adult Acute Bas... Adult Acute Eos... Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Blastic Phase C... Chronic Myelomo... de Novo Myelody... Previously Trea... Recurrent Adult... Recurrent Adult... Refractory Anem... Refractory Anem... Refractory Chro... Relapsing Chron... Secondary Myelo... Stage III Chron... Stage IV Chroni... Untreated Adult... | R(+)XK469 pharmacological... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome | NCT00004918 | Accelerated Pha... Adult Acute Mye... Chronic Phase C... Previously Trea... Refractory Anem... Refractory Anem... Relapsing Chron... | PR1 leukemia pe... Montanide ISA 5... sargramostim laboratory biom... | 19 Years - | National Cancer Institute (NCI) | |
| Tipifarnib in Treating Patients With Myelodysplastic Syndromes | NCT00005845 | Chronic Myelomo... de Novo Myelody... Previously Trea... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... | tipifarnib laboratory biom... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Biological Therapy in Treating Patients With Myelodysplastic Syndrome | NCT00005853 | Leukemia Myelodysplastic... | anti-thymocyte ... etanercept | - | Fred Hutchinson Cancer Center | |
| Biological Therapy in Treating Patients With Myelodysplastic Syndrome | NCT00005853 | Leukemia Myelodysplastic... | anti-thymocyte ... etanercept | - | Fred Hutchinson Cancer Center | |
| Monoclonal Antibody Therapy in Treating Patients With Myelodysplastic Syndrome or Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelogenous Leukemia | NCT00002890 | Leukemia Myelodysplastic... | lintuzumab | 16 Years - | Memorial Sloan Kettering Cancer Center | |
| Fludarabine, Carboplatin, and Topotecan in Treating Patients With Relapsed/Refractory Acute Leukemia or Advanced Myelodysplastic Syndrome | NCT00005593 | Leukemia Myelodysplastic... | carboplatin fludarabine pho... topotecan hydro... | 12 Years - | Case Comprehensive Cancer Center | |
| Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia | NCT00087204 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Blastic Phase C... Chronic Myelomo... de Novo Myelody... Previously Trea... Recurrent Adult... Recurrent Adult... Refractory Anem... Refractory Anem... Relapsing Chron... Secondary Acute... Secondary Myelo... | becatecarin laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes | NCT00997243 | Leukemia Myelodysplastic... | lintuzumab 5-azacytidine | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia | NCT00087204 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Blastic Phase C... Chronic Myelomo... de Novo Myelody... Previously Trea... Recurrent Adult... Recurrent Adult... Refractory Anem... Refractory Anem... Relapsing Chron... Secondary Acute... Secondary Myelo... | becatecarin laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer | NCT00296023 | Chronic Myelopr... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | anti-thymocyte ... filgrastim therapeutic all... busulfan fludarabine pho... methotrexate tacrolimus nonmyeloablativ... peripheral bloo... | 18 Years - 75 Years | University of California, San Francisco | |
| Chemotherapy Plus Biological Therapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer | NCT00004145 | Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | anti-thymocyte ... cyclophosphamid... fludarabine pho... peripheral bloo... | 18 Years - 60 Years | University of Chicago |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
